Plant sources of anti-cancer agents
In the 1950s, scientists began systematically examining natural organisms as a source of useful anti-cancer substances. It has recently been argued that "the use of natural products has been the single most successful strategy in the discovery of novel medicines".
Plants need to defend themselves from attack by micro-organisms, in particular fungi, and they do this by producing anti-fungal chemicals that are toxic to fungi. Because fungal and human cells are similar at a biochemical level it is often the case that chemical compounds intended for plant defence have an inhibitory effect on human cells, including human cancer cells. Those plant chemicals that are selectively more toxic to cancer cells than normal cells have been discovered in screening programs and developed as chemotherapy drugs
Research and development process
Some plants that indicate potential as an anticancer agent in laboratory-based in vitro research – for example, Typhonium flagelliforme, and Murraya koenigii are currently being studied. There can be many years between promising laboratory work and the availability of an effective anti-cancer drug: Monroe Eliot Wall discovered anti-cancer properties in Camptotheca in 1958, but it was not until 1996 – after further research and rounds of clinical trials – that topotecan, a synthetic derivative of a chemical in the plant, was approved for use by the US Food and Drug Administration.
- Camptotheca acuminata
- Catharanthus roseus
- Podophyllum spp.
- Taxus brevifolia
- Euphobia peplus
- Maytenus ovatus
- Herbal medicine
- Experimental cancer treatments
- Chemotherapy regimens
- National Comprehensive Cancer Network
- Alternative cancer treatments
- Cragg, Gordon M.; Newman, David J. (2005). "Plants as a source of anti-cancer agents" (PDF). Journal of Ethnopharmacology. 100 (1–2): 72–9. doi:10.1016/j.jep.2005.05.011. PMID 16009521.
- Shoeb, Mohammad (2008). "Anticancer agents from medicinal plants". Bangladesh Journal of Pharmacology. 1 (2). doi:10.3329/bjp.v1i2.486.
- Tulp, Martin; Bohlin, Lars (2002). "Functional versus chemical diversity: Is biodiversity important for drug discovery?". Trends in Pharmacological Sciences. 23 (5): 225–31. doi:10.1016/S0165-6147(02)02007-2. PMID 12008000.
- Cardenas, ME; Cruz, MC; Del Poeta, M; Chung, N; Perfect, JR; Heitman, J (1999). "Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action". Clin. Microbiol. Rev. 12: 583–611. PMC 88926. PMID 10515904.
- Mohan, S.; Bustamam, A.; Ibrahim, S.; s. Al-Zubairi, A.; Aspollah, M. (2008). "Anticancerous Effect of Typhonium flagelliforme on Human T4-Lymphoblastoid Cell Line CEM-ss". Journal of Pharmacology and Toxicology. 3 (6): 449–456. doi:10.3923/jpt.2008.449.456.
- Syam, Suvitha; Abdul, Ahmad Bustamam; Sukari, Mohd. Aspollah; Mohan, Syam; Abdelwahab, Siddig Ibrahim; Wah, Tang Sook (2011). "The Growth Suppressing Effects of Girinimbine on Hepg2 Involve Induction of Apoptosis and Cell Cycle Arrest". Molecules. 16 (8): 7155–70. doi:10.3390/molecules16087155. PMC 6264672. PMID 21862957.
- "Topotecan (NSC 609699)". National Cancer Institute. Retrieved August 2013. Check date values in:
- "Yew clippings to make chemotherapy". Cancer Research UK. Retrieved August 2013. Check date values in:
- Zarchi, K; Jemec, G. B. (2015). "Actinic Keratosis". Current Problems in Dermatology. Current Problems in Dermatology. 46: 136–42. doi:10.1159/000366549. ISBN 978-3-318-02762-4. PMID 25561218.
- Peddi, P. F.; Hurvitz, S. A. (2014). "Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: Latest evidence and clinical potential". Therapeutic Advances in Medical Oncology. 6 (5): 202–209. doi:10.1177/1758834014539183. PMC 4206612. PMID 25342987.